Studies on the metabolism of the novel antitumor agent [N-methyl- 11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials

Cancer Research

Volumn 57, Issue 11, 1997, Pages 2172-2180

  Osman, Safiye ^a   Luthra, Sajinder K ^a   Brady, Frank ^a   Hume, Susan P ^a   Brown, Gavin ^a   Harte, Robert J A ^a   Matthews, Julian C ^a   Denny, William A ^b   Baguley, Bruce C ^b   Jones, Terry ^a   Price, Pat M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; BLOOD SAMPLING; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; TISSUE DISTRIBUTION;

ACRIDINES; ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; KIDNEY; LIVER; LUNG; MALE; MIDDLE AGED; MYOCARDIUM; NEOPLASMS; PLASMA; RATS; RATS, SPRAGUE-DAWLEY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030947491     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Atwell, G. J., Rewcastle, G. W., Baguley, B. C., and Denny, W., A. Potential antitumour agents. 50. In vitro solid tumour activity of derivatives. N-[2-(dimethylamino)ethyl]ecridine-4-carboxamide. J. Med. Chem., 30: 664-669, 1987.
2. Baguley, B., Denny, VV. A., Atwell, G. J., Rewcastle, G. W., Wilson, W. R. Synthesis, antitumor activity and DNA properties of a new derivative of amsacrine. N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridine- carboxamide. Cancer Res., 44: 3245-3251, 1984.
3. Arlin, Z., Current status of amsacrine combination chemotherapy programs in acute leukaemia. Cancer Treat. Rep., 67: 1607 1612, 1983.
4. Hardy, J. R., Harvey, V. J., Paxton, J. W., Evans, P. C., Smith, S., Grillo-Lopez A., Grove, W., and Baguley, B. C. A Phase I trial of the amsacrine analog 9-[(2-methylsulfonylamino)-phenylamino]-N.5-dimethyl-4-acridinecarboxamide (CI-921). Cancer Res., 48: 6593-6596, 1988.
5. Paxton, J. W., Hardy, J. R., Evans, P. C., Harvey, V. J., and Baguley, B. C. The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)-phenylamino]-4- acridinecarboxamide (CI-921) in a Phase I trial. Cancer Chemother. Pharmacol., 22: 235-240, 1988.
6. Schneider, E., Durkin, S. J., Lawson, P. A., Ching, L-M., Ralph, R. K., and Baguley, B. C. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. Eur. J. Cancer Clin. Oncol., 24: 1783-1790, 1988.
7. Finlay, G. J., Riou, J-F., and Baguley, B. C. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur. J. Cancer., 32A: 708-714, 1996.
8. Robertson, I. G. C., Palmer, D. B., Paxton, J. W., and Bland, T. J. Metabolism of the experimental antitumour agent acridine carboxamide in the mouse. Drug Metab. Dispos., 21: 530-536, 1993.
9. Brady, F., Luthra, S. K., Brown, G., Osman, S., Harte, R. J. A., Denny, W. A., Baguley, B. C., Jones, T., and Price, P. M. Carbon 11-labeling of the antitumor agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man. Appl. Radiat. Isol., 48: 487-492, 1997.
10. Her Majesty's Stationery Office. Home Office's Guidance on the Operation of the Animals (Scientific Procedures) Act 1986. Her Majesty's Stationery Office. 1990
11. 11C]scherring 23390. J. Lab. Comp. Radiopharm., 32: 518-520, 1993.
12. Spinks, T. J., Jones, T., Bailey, D. L., Townsend D. W., Grootoonk S., Bloomfield P. M., Gilardi M. C., Casey, M. E., Sipe, B., and Reed, J. Physical performance of a positron tomography for brain imaging with retractable septa. J. Phys. Med. Biol ., 37: 1637-1655, 1992.
13. Robb, R. A., and Hanson, P. D. A software system for interactive and quantitative visualization of multidimensional biomedical images. Aust. Phys. Eng. Sci. Med., 14: 9-30, 1991
14. In: P. L. Altman and D. S. Dittmer (eds.), Respiration and Circulation (Biological handbooks ). Bethesda. MD: Federation of American Societies for Experimental Biology. Chapter 7. 383-385, 1971.
15. Paxton, J. W., Young, D., Evans, S. M., Kestell, P., and Robertson, I. G. C. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl-]acridine-4-carboxamide after i.v. administration in the mouse. Cancer Chemother. Pharmacol., 29: 379-384, 1992.
16. Paxton, J. W., Young, D., and Robertson, I. G. C. Pharmacokinetics of acridine-4-carboxamide in the rat. with extrapolation to humans. Cancer Chemother. Pharmacol., 32: 323-325, 1993.
17. Evans, S. M. H., Young, D., Robertson, I. G. C., and Paxton J. W. Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose. Cancer Chemother. Pharmacol., 31: 32-36, 1992.
18. Cornford, E. M., Young, D., and Paxton, J. W. Comparison of the blood-brain barrier and liver penetration of acridine antitumour drugs. Cancer Chemother. Pharmacol., 29: 439-444, 1992.